

Accepted Manuscript

Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells

Ailin Li, Hampartsoum B. Barsoumian, Jonathan E. Schoenhals, Taylor R. Cushman, Mauricio S. Caetano, Xiaohong Wang, David R. Valdecanas, Sharareh Niknam, Ahmed I. Younes, Guang Li, Wendy A. Woodward, Maria Angelica Cortez, James W. Welsh



PII: S0304-3835(18)30324-0

DOI: [10.1016/j.canlet.2018.05.005](https://doi.org/10.1016/j.canlet.2018.05.005)

Reference: CAN 13889

To appear in: *Cancer Letters*

Received Date: 6 February 2018

Revised Date: 2 May 2018

Accepted Date: 3 May 2018

Please cite this article as: A. Li, H.B. Barsoumian, J.E. Schoenhals, T.R. Cushman, M.S. Caetano, X. Wang, D.R. Valdecanas, S. Niknam, A.I. Younes, G. Li, W.A. Woodward, M.A. Cortez, J.W. Welsh, Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.05.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1), involved in the catabolism of tryptophan (Trp) to kynurenine (Kyn) is an important regulator of tumor-mediated immunosuppression implicated in resistance to anti-PD1 immunotherapy. We investigated the role of IDO1 in an anti-PD1-resistant lung cancer model (344SQ_R) compared to the parental 344SQ tumors (344SQ_P). IDO1 was overexpressed in tumor-infiltrating leukocytes, and plasma Kyn levels were increased, in 344SQ_R vs. 344SQ_P. The IDO1 inhibitor INCB023843 retarded tumor growth and reduced lung metastases in 344SQ_R. IDO1 was expressed at higher levels in F4/80⁺Gr1^{int}CD11b⁺ myeloid-derived suppressor cells (MDSCs) that were prominent in 344SQ_R. The INCB023843 reduced IDO1 expression and percentages of these MDSCs while increasing CD8⁺ T cells infiltration, hence reactivating antitumor T-cell responses in 344SQ_R. Therefore, IDO1 inhibition holds promise for treating lung cancer that does not respond to anti-PD1 therapy.

Download English Version:

<https://daneshyari.com/en/article/8434210>

Download Persian Version:

<https://daneshyari.com/article/8434210>

[Daneshyari.com](https://daneshyari.com)